PDCD1 and melanoma: A third study showed that conventional nonsteroidal anti-inflammatory drugs and COX-2 inhibitors combined with an anti-PD-1 monoclonal antibody promoted a much more rapid regression of mouse melanoma tumors than the anti-PD-1 antibody alone did (27).